Table Ronde with Clarissa Desjardins (Congruence Therapeutics)

​Table Ronde and Ax.c are teaming up for the third event in a series designed to bring founders closer to real first-hand lessons from leading local entrepreneurs who built in Montreal and successfully scaled beyond it.

​Clarissa Desjardins has done what few Canadian founders ever do: she built a Montreal biotech, took it public on Nasdaq and sold it for US$1.3B. That company was Clementia, and Ipsen’s acquisition of it in 2019 is one of the biggest deals in Canadian biotech history.

​Then she started over with Congruence Therapeutics. Congruence uses AI to design drugs for diseases caused by misfolded proteins. It has raised over US$100M, and its first drug is already in human trials.

​If you’re building in life sciences, deep tech or AI, don’t miss this one.

​We’ll discuss:

• ​4 companies in 30 years

• ​Montreal → Nasdaq → US$1.3B exit

• ​Why she started over after a billion-dollar sale

• ​Designing medicines with AI

• ​Raising US$100M+ for deep science

​Please proceed to the 4th floor when you get to Ax.c.

​What is Table Ronde?

​Table Ronde is Montreal's monthly fireside chat for builders. Each month, we sit down with one founder, CEO or investor who's been through it, and get the real story: the hard calls, the near-misses, and what they'd do differently.

​One guest, one honest conversation, open Q&A, and a room full of people building something.

​Past guests include the founders of Dialogue, Stay22, nesto, Goodfood and Novisto.

​35+ talks · 3,500+ community · 120+ builders in the room every month